Investigating a rare and aggressive blood cancer called BPDCN
Official title: Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Funded at Dana-Farber Cancer Inst · NIH-10855766 · Data updated 2026-11-12
This study is looking at a rare and serious blood cancer called BPDCN to find out how certain genetic changes affect the disease, with the hope of discovering new treatments that could help patients like you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | February 1, 2018 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $377,137 |
| NIH project number | 5R37CA225191-07 |
| Project ID | NIH-10855766 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
✕Less likely to help
Patients with other types of cancers or hematologic disorders unrelated to BPDCN may not benefit from this research.
What this research studies
This research focuses on blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer that often leads to fatal outcomes within a year of diagnosis. The study aims to understand the genetic mutations that drive this disease, particularly focusing on RNA splicing factors and their role in cancer progression. By utilizing advanced DNA sequencing and genetically engineered models, researchers will explore how specific mutations contribute to the transformation of dendritic cells and identify potential treatment vulnerabilities. This approach may lead to the development of targeted therapies for patients suffering from BPDCN.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with BPDCN.
How similar studies have gone: Previous research has shown promising results in targeting genetic mutations in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Lane, Andrew a — Dana-Farber Cancer Inst
- Study coordinator: Lane, Andrew a
Related research
Other NIH-funded projects on the same topics.
-
Complement and clotting in JAK2V617F myeloproliferative neoplasms
A short, patient-friendly study will look at how a specific mutation in blood cells may trigger the body’s complement system to cause clots in people with myeloproliferative neoplasms.
-
Endothelial contribution to blood-clotting in myeloproliferative neoplasms
This project explores how the lining of blood vessels may drive dangerous clots in people with myeloproliferative neoplasms (MPNs).
-
Hypoxia-inducible factors and neutrophil diversity in blood clotting in myeloproliferative neoplasms
A physician-scientist is training over five years to uncover how low-oxygen signals and diverse neutrophils drive dangerous clots in people with myeloproliferative neoplasms, with the goal of finding new treatment targets.
-
Inherited genetic risks shaping myeloid cancer initiation
A research project at Boston Children’s Hospital is exploring how inherited genetic differences may push blood stem cells toward the start of myeloproliferative neoplasms, with potential implications for earlier detection and prevention.
-
Understanding why some myeloproliferative neoplasm patients resist interferon therapy
Researchers are studying why interferon-alpha works for some blood cancer patients but not others, by looking closely at stem cells from CALR-mutated myeloproliferative neoplasms.
-
Genetic and epigenetic factors shaping response in advanced myeloproliferative neoplasms
This grant looks at how genetic and epigenetic differences influence how patients with advanced myeloproliferative neoplasms respond to therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.